Spire Healthcare Regulatory News (SPI)

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic")

FOR IMMEDIATE RELEASE

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

20 November 2017

Announcement Regarding Spire Healthcare Group plc

Further to the announcements made by Spire Healthcare Group plc ("Spire") and Mediclinic in relation to Mediclinic's possible offer for the entire issued and to be issued share capital of Spire not already owned by it or its subsidiaries, Mediclinic confirms that, following further consideration and discussions with the independent directors of Spire, it was unable to reach agreement on the terms of a transaction.

Accordingly, Mediclinic does not intend to make an offer for Spire and is bound by the restrictions under Rule 2.8 of the City Code on Takeovers and Mergers (the "Code").

Mediclinic is disappointed that it could not reach an agreement with the independent directors of Spire but will continue to take a disciplined approach to capital allocation to ensure investments are in the best interests of Mediclinic shareholders. Mediclinic has every intention of remaining a supportive shareholder of Spire.

For the purposes of Rule 2.8 and other relevant provisions of the Code, Mediclinic reserves the right to announce an offer or possible offer or make or participate in an offer or possible offer for Spire or to take any other action which would otherwise be restricted under Rule 2.8 of the Code, within the next six months following the date of this announcement, in the circumstances set out in Note 2 to Rule 2.8 of the Code or otherwise with the consent of the UK Takeover Panel.

A copy of this announcement will be available on Mediclinic's corporate website at www.mediclinic.com. The content of this website is not incorporated into, and does not form part of, this announcement.

Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in South Africa and the NSX in Namibia.

Enquiries

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

ir@mediclinic.com

+44 (0)20 3786 8181

FTI Consulting (PR adviser to Mediclinic)

Debbie Scott (UK) +44 (0)20 3727 1000

Frank Ford (South Africa) +27 (0)21 487 9000

Corporate broker: Morgan Stanley & Co. International plc

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Limited 

Morgan Stanley & Co. International plc ("Morgan Stanley") which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the UK is acting as co-financial adviser to Mediclinic and no one else in connection with the matters set out in this announcement. In connection with such matters, Morgan Stanley, its affiliates (including without limitation Morgan Stanley South Africa (Pty) Limited) and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein.

Rand Merchant Bank, a division of FirstRand Bank Limited ("RMB") is acting as co-financial adviser to Mediclinic and no one else in connection with the matters referred to in this announcement. In connection with such matters, RMB, its affiliates and its and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person other than Mediclinic for providing the protections afforded to their clients or for providing advice in connection with the contents of this announcement or any other matter referred to herein.

The release, publication or distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and, therefore, persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply which such restrictions may constitute a violation of the securities law of any such jurisdiction.